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Abstract Autism spectrum disorder (ASD) is character-
ized by deficits in language development and social
cognition and the manifestation of repetitive and restric-
tive behaviors. Despite recent major advances, our un-
derstanding of the pathophysiological mechanisms lead-
ing to ASD is limited. Although most ASD cases have
unknown genetic underpinnings, animal and human cel-
lular models of several rare, genetically defined
syndromic forms of ASD have provided evidence for
shared pathophysiological mechanisms that may extend
to idiopathic cases. Here, we review our current knowl-
edge of the genetic basis and molecular etiology of ASD
and highlight how human pluripotent stem cell-based
disease models have the potential to advance our under-
standing of molecular dysfunction. We summarize land-
mark studies in which neuronal cell populations generat-
ed from human embryonic stem cells and patient-derived
induced pluripotent stem cells have served to model
disease mechanisms, and we discuss recent technological
advances that may ultimately allow in vitro modeling of
specific human neuronal circuitry dysfunction in ASD.
We propose that these advances now offer an unprece-
dented opportunity to help better understand ASD path-
ophysiology. This should ultimately enable the
development of cellular models for ASD, allowing drug
screening and the identification of molecular biomarkers
for patient stratification.
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Autism is a neurodevelopmental disorder defined by impair-
ments in social interaction, deficits in verbal and nonverbal
communication, and the display of stereotyped and repetitive
behaviors. Comorbid symptoms include intellectual disability,
seizures, anxiety, aggression, and sleep disorders. Typical au-
tism is at the extreme end of the autism spectrum, which also
includes Asperger's syndrome, childhood disintegrative disor-
der and a set of disorders referred to as pervasive developmen-
tal disorder (PDD) not otherwise specified. The prevalence of
autism spectrum disorder (ASD) is estimated to range between
∼25 and ∼110 in every 10,000, placing a substantial socioeco-
nomic burden on families and society (Baird et al. 2006;
Kogan et al. 2009). Although pharmacotherapy can manage
ASD comorbidities, it does not address the core deficits. Cur-
rent treatments are focusing on educational and behavioral
interventions aimed at ameliorating maladaptive behaviors
and promoting social interactions (Myers and Johnson 2007).
A prerequisite for the development of pharmacological
agents targeting the core symptoms of ASD is a deeper un-
derstanding of the underlying pathophysiology. ASD has a
strong genetic component and a small fraction of ASD cases is
caused by defined genetic aberrations. Several mouse models
of these syndromic forms of autism have provided insight into
dysregulated pathways. The advent of somatic cell
reprogramming now enables the study of ASD neurobiology
using patient-derived cells. Ectopic expression of the four
transcription factors Klf-4, Oct4, Sox2, and c-Myc induces
reprogramming of somatic human cells to a pluripotent state
(Takahashi et al. 2007; Takahashi and Yamanaka 2006). These
human induced pluripotent stem cells (hiPSCs) retain the
genetic composition of the cells they have been derived from
(with the exception of stably integrated transgenes in the case
of retro- or lentiviral approaches) and, owing to their plurip-
otent state, can be differentiated into cell types of all three
germ layers. hiPSCs have characteristics similar to those of
human embryonic stem cells (hESCs), derived from the inner
cell mass of the embryonic blastocyst, and together hiPSC and
hESCs are referred to as human pluripotent stem cells (hPSCs)
in this review. Although reprogramming was initially
established using dermal fibroblasts and using integrating
viral vectors, recent advances allow derivation of hiPSCs from
cell types accessible by less invasive methods, such as from
keratinocytes (Aasen et al. 2008), peripheral blood T lympho-
cytes (Brown et al. 2010; Seki et al. 2011), and exfoliated
renal epithelial cells found in urine samples (Zhou et al. 2011,
2012). In combination with efficient transgene-free
reprogramming (Fusaki et al. 2009), these improvements fa-
cilitate the generation of hiPSCs from patients enrolled in
clinical trials or studies.
A major limitation of hiPSC-based disease models is the
fact that they necessitate the use of hiPSC lines generated from
unaffected individuals as controls. Differences in genetic
makeup are likely to contribute to interclonal variability be-
tween lines, further adding to differences in their properties
caused by the reprogramming procedure itself (Hu et al.
2010). While in practice, these issues are addressed by gener-
ating multiple hiPSC lines from multiple patients and control
individuals, the effect size of the phenotypes to be observed is
usually unknown, making it impossible to estimate the num-
ber of cell lines required a priori. These barriers inherent in
hiPSC-based disease modeling can be circumvented by
targeted genetic manipulation of hPSCs. Sequence-specific
designed zinc finger nucleases (ZFNs) or transcription
activator-like effector nucleases (TALENs) can be used to
generate a double strand break at a specific locus in the
genome of hPSCs, allowing gene targeting via homology-
directed repair or non-homologous end joining (Ding et al.
2013a; Lombardo et al. 2007). ZFNs and TALENs are now
readily available (Kim et al. 2013; Xiao et al. 2013), enabling
the disruption or mutation of virtually any gene. Recently
developed advanced sequence-specific nuclease systems
show improved targeting efficiency, making deletion even of
large genomic segments possible, and thus open the door to
model diseases caused by copy number variations (CNVs)
(Cong et al. 2013; Ding et al. 2013b).
In this review, we provide a summary of the potential
application of hPSCs for the generation of cellular models of
ASD. We illustrate how insights from human genetic and
transcriptome pathway studies as well as from mouse models
inform the design of relevant hPSC models and discuss recent
advances towards the generation of hPSC-derived neuronal
populations that may enable modeling of human circuitry
dysfunction in ASD.
Human genetics, mouse models, and pathway analyses:
guiding the selection of appropriate hPSC models
Human genetics
ASD is highly heritable, with concordance rates in monozy-
gotic twins estimated to be as high as 90% (Bailey et al. 1995;
Steffenburg et al. 1989). Even though the causes of ASD are
largely unknown, heritability provides a strong rationale for
modeling ASD using genetically modified hPSCs and patient-
derived hiPSCs, since neuronal populations derived from
them will carry the causative genetic aberrations, which may
lead to relevant neuronal dysfunction observable in vitro.
Despite high heritability, the upper limit of the fraction of
patients that harbor known genetic mutations likely causative
for ASD is currently estimated at ∼30–45 % (Schaaf and
Zoghbi 2011; Stein et al. 2013), indicating that the majority
of genetic defects remain to be identified in idiopathic cases.
Indeed, recent results from CNV (Gilman et al. 2011; Levy
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et al. 2011; Sanders et al. 2011) and exome sequencing (Lim
et al. 2013; Michaelson et al. 2012; Yu et al. 2013) studies in
large autism cohorts point to the involvement of hundreds of
genes conferring ASD risk when mutated, disrupted, or du-
plicated. Overall, these genetic studies support a largely poly-
genic susceptibility model in which a minority of patients
carries one of a few highly penetrant genetic aberrations,
while the majority of patients harbor a small subset of hun-
dreds of genetic aberrations that individually convey sub-
threshold risk (Neale et al. 2012). Models of genetically
defined, syndromic forms of autism have provided critical
insights into disease-causing mechanisms. They support the
notion that despite the genetic heterogeneity, pathophysiolog-
ical trajectories of ASD converge onto a limited number of
affected pathways. Future research will address whether these
emerging concepts will extend to idiopathic cases of ASD.
Many of these high-risk alleles are recurrent CNVs that
affect large arrays of genes, while others are point mutations
or small insertions and deletions (indels) which, although
individually unique, collectively converge on a limited set of
genes (Kelleher and Bear 2008). Intriguingly, most of these
genes fall into two broad functional classes, namely, genes
predominantly involved in regulating synapse structure and
function (e.g., SHANK3, CNTNAP2, NRXN1, NLGN3/4X)
and those involved in transcriptional and/or translational con-
trol (e.g., TSC1/2, MECP2, NF1, PTEN) (see review by
Bourgeron et al. in this issue). The large numbers of genes
affected in CNVs (which are readily detected using genome-
wide microarrays and thus have been found more frequently
than smaller indels or mutations, whose detection requires
some form of targeted sequencing) present a challenge for
the identification of causal genes. Network-based approaches
for the analysis of genetic associations, using as input data
genes affected by CNVs fromASD patients, may help address
this challenge. Figure 1 shows a roadmap illustrating how
insights from network-based analyses of genetic and
transcriptomic data from ASD patients can inform the design
of relevant ASD cellular models.
In one such network-based approach, termed NETBAG
(Gilman et al. 2011), a large set of gene descriptors was first
used to construct a background network of genes that are
clustered based on their likelihood of contributing to a shared
phenotype. When 433 candidate genes affected by 47 de novo
CNVs from a large autism patient cohort were then mapped
onto the network and interrogated for their capacity to support
the preformed connections, several single genes within CNVs
emerged as significantly associated (Gilman et al. 2011).
HPSC lines with gene disruptions in these candidate genes,
or in genes directly linked within the same cluster, will expand
the range of human cellular ASD models and will enable
direct probing of implicated pathways. In addition, such
models will subsume genetic aberrations shared by several
patients. Recent advances in genome editing technology now
make it possible to construct such synthetic hPSC-based
models, including those for which patient cells are not avail-
able for reprogramming (Fig. 1). Common molecular dys-
function observed in these models will also aid in patient
stratification.
Despite the paucity of knowledge of “culprit” genes in
CNVs, these disorders have advanced our understanding of
autism pathophysiology. CNVs where deletions and recipro-
cal duplications cause largely overlapping clinical pheno-
types, and those where the reciprocal change leads to oppos-
ing phenotypes, have been particularly instructive. For exam-
ple, a CNV on 16p11.2 deleting ∼600 kb and encompassing
∼25 known coding genes is associated with autism, while
duplication of the same region is associated with autism and
schizophrenia (McCarthy et al. 2009). 16p11.2 deletions and
duplications are also linked to macrocephaly and microceph-
aly, respectively (McCarthy et al. 2009). In contrast, deletion
of a ∼1.5-Mb chromosomal segment on 7q11.23 containing
∼28 genes causes Williams syndrome (Merla et al. 2010).
Individuals affected by this disorder have generally good
verbal skills relative to their intelligence quotient and, strik-
ingly, tend to be exceedingly sociable, approach strangers
readily and hyperfocus on the eyes of others (Mervis and
John 2010). In contrast, duplication of this region is associated
with autism, mental retardation, language impairment, and
epilepsy (Mervis and John 2010; Sanders et al. 2011). Lastly,
loss of a ∼5-Mb region on 15q11-13, harboring 10–15 coding
genes, on the maternal chromosome causes Angelman syn-
drome (Pembrey et al. 1989), characterized by developmental
delay, speech impairment, ataxia, and a unique combination of
behavioral phenotypes that include a generally happy dispo-
sition, frequent smiling and laughing, and excitability
(Williams et al. 2006). In contrast, individuals with duplica-
tions or triplications encompassing this region are autistic,
with penetrance of ASD phenotypes correlating with CNV
dosage (Hogart et al. 2010). Thus, syndromes related to one
another by reciprocal CNVs illustrate that opposing gene
dosage can lead to either converging or opposing clinical
phenotypes. The example of the 16p11.2 CNV suggests that
the autism phenotype may not be linked to its specific copy
number (and, consequently, to gene dosage). Analyses of
CNVs in rodents and humans have shown that, instead, it
may be the structural change in the genome caused by the
CNV that contributes to the phenotype. Support for this hy-
pothesis comes from rodent studies of CNV-dependent dosage
sensitivity of gene expression. Here, an only modest correla-
tion between copy number and gene dosage was observed in
general, with particularly low correlation in the brain
(Henrichsen et al. 2009a,b; Reymond et al. 2007). These
observations have major implications for modeling functional
consequences of CNVs in mouse models (see below).
Nevertheless, hiPSC models of these syndromes may help
understand how and where on the pathophysiological
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trajectory these reciprocal CNV syndromes converge or di-
verge. Although knowledge of the critical genes in these
CNVs is still limited, experiments in zebrafish have linked
the head size phenotype in 16p11.2 CNVs to dysregulation of
the neural progenitor cell (NPC) proliferation gene KCTD13 ,
which codes for a protein that interacts with the proliferating
cell nuclear antigen (Golzio et al. 2012). The finding that a
subset of Angelman patients harbor point mutations in
UBE3A within the 15q11-13CNV strongly suggests that dys-
function of this gene, coding for an E3 ubiquitin ligase, is
primarily responsible for the phenotype (Kishino et al. 1997).
Targeted genetic manipulation of these candidate genes in
hPSCs will help identify the molecular underpinnings of
ASD and may ultimately serve as cellular models (Fig. 1).
Further advances, alongside reductions in the costs associ-
ated with deep sequencing, will make whole genome sequenc-
ing of large patient cohorts feasible in the near future. These
studies will undoubtedly reveal additional small risk-
conferring genetic defects (indels and point mutations) outside
of the coding regions of known genes, particularly in promoter
and enhancer regions, where variation in human populations
is higher than in coding regions, and within long non-coding
ribonucleic acids (RNAs), which have recently come into
focus as important players in neurogenesis and neuropsychi-
atric disorders (Lin et al. 2011). These advances will likely
expand the set of informative genotypes, which can be
exploited to model ASD with human hPSCs.
Insights from transcriptome analyses in human brain
postmortem brain
Volumetric magnetic resonance imaging (MRI) studies, com-
bined with structural analyses of postmortem brains of ASD
patients, have identified associated neuroanatomical and cel-
lular aberrations. Overall, these findings point to increased
brain growth beginning in the first postnatal year, persisting at
least into early childhood (Courchesne et al. 2007). More
detailed analyses have revealed changes in neuronal size,
number, and density, as well as defects in neuronal organiza-
tion in frontal and temporal cortex, anterior cingulate, amyg-
dala, and cerebellum (Amaral et al. 2008; Schumann and
Nordahl 2011). Although these alterations are likely due to
defects in regulation of neuronal differentiation, proliferation,
and migration, their molecular underpinnings remain elusive.
Transcriptome analyses of these brain regions in large cohorts
of ASD patients may help identify commonly dysregulated
Fig. 1 A roadmap towards ASD
modeling in hPSCs. Genomic
analysis from ASD patients
identifies those who harbor
genetic defects that might be
causal and hiPSCs from these
patients can be generated from
biopsy material. Insight into
shared pathophysiological
trajectories comes from pathway
analyses of genetic aberrations, as
well as from network-based
analyses of gene expression in
postmortem brains of ASD
patients. Guided by the
identification of pathways
commonly dysregulated in larger
subsets of patients, this
knowledge informs the selection
of genes to be targeted to create
additional ASDmodels. If present
in the patient cohort, these can be
generated by somatic cell
reprogramming. Alternatively,
additional genotypes can be
obtained from normal hPSCs via
targeted genetic manipulation
using genome editing. Control
hPSCs may also be generated
from patient hPSCs by reverting
the causative genetic aberration
using genome editing
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pathways converging from the heterogeneous genetic back-
ground of the disorder (Fig. 1). Such studies, however, have
only recently begun to emerge (Chow et al. 2012; Voineagu
et al. 2011).
In a seminal paper, Geschwind and colleagues analyzed the
transcriptomes of frontal and temporal cortex and cerebellum
from 19 postmortem brains from idiopathic cases of ASD and
from 17 control individuals (Voineagu et al. 2011). An anal-
ysis approach based on identification of gene coexpression
networks revealed that the most significantly ASD-correlated
module of functionally related genes was enriched for genes
involved in synaptic function, as well as for known autism
susceptibility genes. Thus, in addition to confirming involve-
ment of synaptic dysfunction in ASD, these findings strongly
suggest that transcriptomic approaches can identify molecular
commonalities in ASD brains, and we can now address
whether hiPSC-derived neurons can identify these molecular
signatures. The dominant module was anchored by A2BP1 ,
the gene coding for the neuron-selective splicing factor
RBFOX1, thus implicating splicing dysregulation in ASD
(Fogel et al. 2012). Since A2BP1 itself had previously been
identified as an autism susceptibility gene in humans (Martin
et al. 2007), these results provide a strong rationale for creat-
ing hPSC-based ASD models with defects in this gene. In-
triguingly, the study also showed that differences in gene
expression patterns between frontal and temporal cortex were
attenuated in ASD brains, suggesting defects in cortical spec-
ification, patterning, and/or organization (Voineagu et al.
2011). Thus, similar to network-based analyses of de novo
CNVs in ASD patients, postmortem transcriptome studies
pinpoint pathways commonly dysregulated in ASD (Fig. 1).
Transcriptome profiles will also help validate and benchmark
hPSC-based models—either obtained by cellular
reprogramming of patient-derived cells or generated by ge-
nome editing in normal hPSCs—of critical genes within these
pathways and will be crucial to test the relevance of pathways
implicated in ASD pathophysiology.
Mouse models
Mouse models of genetically defined, syndromic forms of
ASD phenocopy core autism deficits and have provided crit-
ical insight into pathophysiological mechanisms. In mouse
models of fragile X syndrome, Rett syndrome and tuberous
sclerosis complex, reversal of autism phenotypes by pharma-
cological and/or genetic intervention has been achieved after
brain development. These studies suggest that pharmacologi-
cal intervention may be a viable disease-modifying approach
in both children and adults. However, at least in part due to
differences in trajectories of brain development and anatomy,
translation from mouse models to the human condition has
been particularly difficult for central nervous system (CNS)
diseases (Dragunow 2008). Human cellular models that
recapitulate human-specific aspects of brain development
and anatomy, particularly cortical specification and organiza-
tion, can help to bridge this gap in translational ASD research.
Differences in the genomic make-up and transcriptional
regulation between mouse and human pose a challenge to
model human genetic variants, particularly CNVs, in mouse.
When genomic regions affected by CNVs are not syntenic
between mouse and human, the mouse chromosomal region
corresponding to its human counterpart will not contain the
same set of genes. Since CNVs have been shown to affect
expression patterns of genes distal to the CNV breakpoints
(Reymond et al. 2007), this caveat also applies to chromo-
somal regions surrounding the CNV. Moreover, human-
specific transcriptional processes, such as alternative promoter
usage and alternative splicing, are also not replicated in a
heterologous system. Thus, hPSC-based disease models of
ASD caused by CNVs may be more likely to recapitulate
human disease etiology.
The fact that some ASD patients carry two genetic defects
suggests that these may act in concert, supporting a multi-hit
model for ASD. For example, ASD patients with a deletion at
16p12.1 are more likely to harbor an additional CNV than
would be expected by chance (Girirajan et al. 2010). In
addition, three patients found to carry mutations in the synap-
tic scaffolding protein SHANK2 additionally harbored CNVs
in 15q11-13 (Leblond et al. 2012), a region previously impli-
cated in ASD (see above). Modeling these two-hit genotypes
in mouse would require construction of double-knockout
mice; a more direct path would therefore be the use of
patient-derived hiPSCs for modeling of ASD caused by mul-
tiple genetic aberrations.
In the past, the vast majority of genetically defined ASD
mouse models have been built to genocopy mutations found
in the patient population. Our growing understanding of the
common molecular pathways dysregulated in different forms
of ASD has now begun to enable the design of novel mouse
models (or the use of pre-existing models that have not pre-
viously been considered as ASD models) that may subsume
aspects of ASD pathology arising through diverse etiologies.
A first glimpse into this new direction in ASD research has
been provided by the finding that RBFOX1 is downregulated
in brains of idiopathic ASD patients, as described above
(Voineagu et al. 2011). Excitingly, a CNS-specific Rbfox1
knockout mouse has been shown to have an increase in
neuronal excitability and susceptibility to spontaneous sei-
zures, a common ASD comorbidity (Gehman et al. 2011). It
will be interesting to see whether this mouse also displays core
behavioral phenotypes of autism.
One of the central hypotheses for molecular mechanisms
shared among different forms of ASDs is aberrant regulation
of translation causing increased protein synthesis (Kelleher
and Bear 2008). For example, a positron emission
spectroscopy imaging study of children with pervasive
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developmental disorder showed a positive correlation of au-
tism index scores with protein synthesis rates in language
brain regions (Shandal et al. 2011). In addition, translation is
the final common mechanism regulated by the fragile X
mental retardation protein (FMRP) andmTOR pathways, both
strongly linked to autism (see below). Transgenic mice mildly
overexpressing eIF4E, the rate-limiting factor in the assembly
of the translation initiation complex, show autistic-like behav-
iors, increased miniature excitatory postsynaptic current
(mEPSC) frequency and amplitude and enhanced hippocam-
pal metabotropic glutamate receptor (mGluR)-mediated long-
term depression (LTD) (Santini et al. 2013). Similarly, mice
null for one of the three eIF4E-binding proteins (Eif4ebp2
knockout), which sequester eIF4E, display autism-related def-
icits and an increased ratio of excitatory to inhibitory synaptic
inputs (Gkogkas et al. 2013). Strikingly, among 24 autism-
relevant proteins examined in both models, only neuroligins
(Nlgn1-4 ) showed enhanced translation, indicating strong
selectivity in the genes affected by the loss of eIF4E-
dependent translational control (Gkogkas et al. 2013). The
ASD-like phenotypes could be reversed byNlgn1 knockdown
and by intracerebroventricular infusion of the small-molecule
inhibitor of cap-dependent translation, 4-EGI (Santini et al.
2013). Translation dysfunction thus links upstream signaling
defects to downstream synaptic dysfunction, strongly impli-
cating translation hyperfunction as a defect common in both
syndromic and idiopathic ASD. The advent of genome editing
now makes it possible to similarly create hPSCs with transla-
tion dysregulation, paving the road towards human cellular
models of idiopathic ASD (Fig. 1).
Existing hiPSC models of ASD: insights from genetically
defined cases
Identification of phenotypes in hiPSC-based models of ASD
has been achieved in four syndromic forms of ASD with
known single gene defects: Rett syndrome (RTT), Phelan-
McDermid Syndrome (PMDS), Timothy syndrome (TS),
and fragile X syndrome (FXS). These studies have paved
the way for the use of hiPSC-derived neuronal populations
as cellular models of ASD. Electrophysiological analyses of
hiPSC-derived neurons have demonstrated fundamental neu-
ronal firing properties and spontaneous inhibitory and excit-
atory currents, demonstrating synaptic connectivity. Although
the neurons of the middle to upper cortical layers of the human
cortex provide the intracortical circuitry that is among those
thought to be perturbed in ASD, these types of neurons are not
generated in basic hPSC differentiation protocols. Neverthe-
less, since more recent differentiation protocols have begun to
address neuronal region specificity, these hPSC lines can now
be used for more detailed analyses of neuronal function at the
network and circuit levels (see below).
Rett syndrome
RTT is a severe X-linked neurodevelopmental disorder that
occurs in approximately 1 in 10,000 female births and confers
a highly increased risk of developing autism-like behaviors
and seizures (Chahrour and Zoghbi 2007). RTT was the first
PDD for which a genetic cause could be identified (Amir et al.
1999) and, more than 10 years later, the first PDD for which
hiPSC-based models were established (Marchetto et al. 2010).
Thus, animal and cellular models of RTT have become pro-
totypical for understanding the molecular pathophysiology of
RTT and have nurtured the hope that insights gained from
them may extend to other ASDs. Typical RTT is caused by
defects in the gene encoding the transcriptional regulator,
methyl CpG binding protein 2 (MECP2), involved in tran-
scriptional regulation via alteration of chromatin structure
(Baker et al. 2013). Clinical manifestations of RTT include
severe intellectual disability, loss of language, stereotypic
hand wringing, and motor abnormalities.
Even prior to the identification of MECP2 as the gene
affected in RTT, morphological alterations to neuronal struc-
ture had been observed in human postmortem tissue, notably
small neuronal size and reduced dendritic arbors in specific
cortical areas and layers (Armstrong et al. 1995, 1998).
Strikingly, these abnormalities were subsequently found
in mice mutant for Mecp2 (Chen et al. 2001; Kishi and
Macklis 2004). Although an in vitro approach using cultured
dissociated neurons from these mice did not find any effects
on dendritic branching or complexity (Chao et al. 2007),
hiPSC-derived neurons from RTT patients and hESC-
derived MECP2 hemizygous neurons, created by genome
editing, also have significantly reduced cell soma size and
dendritic branching (Cheung et al. 2011; Marchetto et al.
2010). MECP2 mutant neurons showed a global reduction
in transcriptional output (Yazdani et al. 2012), with levels of
actively transcribed genes being particularly affected (Li et al.
2013). Synaptic deficits have been observed in models span-
ning from human RTT hiPSC- (Marchetto et al. 2010) and
hESC-derived neurons (Li et al. 2013), iPSC-derived neurons
from mice mutant for Mecp2 and mouse mutant neuronal
cultures (Chao et al. 2007), in vitro acute brain slices from
mutant mice (Dani et al. 2005), and even, at least to a limited
extent, to in vivo data frommutant mice (Chao et al. 2007). In
the aggregate, these data suggest that, in the absence of
MECP2, neurons fail to maintain gene expression at levels
critical for neuron-specific functions, including activity-
dependent transcription (Li et al. 2013).
Electrophysiological analysis of spontaneous miniature ex-
citatory and inhibitory postsynaptic currents (mEPSCs and
mIPSCs) can impart information on the number and type of
synaptic connections in a neural network. HiPSC-derived
neurons from patients with RTT show reduced frequency
and amplitude of mEPSCs and, to a lesser extent, mIPSCs
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(Marchetto et al. 2010). Combined with data demonstrating
fewer puncta of a presynaptic marker of excitatory synapses,
the lower frequency indicates that RTT neurons produce fewer
synapses. The reduction in amplitude suggests a concomitant
reduction in postsynaptic receptors. While these abnormalities
have been described in various rodent models of ASD (Chao
et al. 2007; Peca et al. 2011), considerable care needs to be
taken in their interpretation, given that in vivo developmental
and in vitro cell line variability can be high. Moreover, the
hiPSC-derived RTT neurons were a mixture of glutamatergic
and GABAergic neurons with unknown regional identity. A
detailed study of iPSC-derived neurons from Mecp2 mutant
mice found reductions in mEPSC frequency in female hetero-
zygotes, but no change in mEPSC amplitude or any abnor-
mality in neurons from male heterozygotes (which have no
MECP2 protein) (Farra et al. 2012). However, these studies
did find consistent abnormalities in action potential amplitude
and rise time, sodium currents, and the number of action
potentials generated by a given stimulus (Farra et al. 2012).
Although these detailed electrophysiological analyses have
yet to be performed in hPSC-based models of RTT, analyses
using multielectrode arrays (MEAs) unveiled reduced sponta-
neous action potential rates in the hESC-based RTTmodel (Li
et al. 2013). Moreover, hiPSC-derived RTT neurons showed a
reduced frequency of calcium transients under conditions
selective for synaptically connected neurons (Marchetto
et al. 2010). In the aggregate, these data point to alterations
in network activity and connectivity in RTT neurons.
A candidate approach, informed by the knowledge of re-
duced excitatory drive and synaptic connections, led to the use
of insulin-like growth factor 1 (IGF-1) in mouse models of
RTT. Here, administration of IGF-1 to mice mutant forMecp2
resulted in a partial reversal of many aspects of the phenotype,
including the synaptic abnormalities (Tropea et al. 2009).
Excitingly, IGF-1 applied to hiPSC-derived RTT neurons
rescued the reduction in excitatory synapses (Marchetto
et al. 2010). Similarly, the reduction in protein synthesis seen
in hESC-derivedMECP2 mutant neurons, created by genome
editing, could be rescued by application of brain-derived
neurotrophic factor (BDNF) or IGF-1 (Li et al. 2013). These
observations provide a first glimpse of the possibility of using
hPSC-derived RTT neurons as an ASD model for drug
screening.
Phelan-McDermid Syndrome
P h e l a n -M cD e rm i d S y n d r om e ( PMDS ) i s a
neurodevelopmental disorder caused by deletion of of the
SHANK3 gene on the terminal end of chromosome 22 (also
known as 22q13 deletion syndrome). It causes a wide range of
symptoms including seizures, intellectual disability and sleep
disorders, as well as being strongly associated with ASD
(Phelan and McDermid 2012). Recently, hiPSC-derived
neurons have been generated from PMDS patients and were
found to have significant deficits in excitatory synaptic trans-
mission. Not only were these deficits rescuable by expression
of SHANK3 itself, but they were also corrected by pharma-
cological treatment with IGF-1 (Shcheglovitov et al. 2013).
These results add weight to the concept that synaptic abnor-
malities may be treatable by pharmacotherapy, and indeed that
where diverse genetic defects converge on similar synaptic
dysfunction there may be commonalities in treatment options.
Timothy syndrome
Timothy syndrome (TS) is an extremely rare autosomal dom-
inant multisystem disorder caused by mutations in
CACNA1C , coding for the alpha-1 (voltage sensor and pore-
forming) subunit of the L-type voltage-gated calcium channel
CaV1.2 (Splawski et al. 2004, 2005). A member of the long
QT family of syndromes, TS causes prolongation of the
cardiac QT interval in affected individuals. Patients with clas-
sic (type 1) TS harbor a recurrent de novo missense mutation
(Gly→Arg) at position 406 in exon 8A. Approximately 25
patients with classic TS have been described, while two pa-
tients with a more severe variant of TS (atypical or type 2 TS)
have a Gly→Arg mutation in the more highly expressed
alternative exon 8 (Splawski et al. 2006). As CACNA1C is
expressed in multiple tissues, mutation causes dysfunction in
multiple organs, including syndactyly (in 100 % of type 1
cases), congenital heart disease (61 %), cardiac arrhythmia
(84 %), immune deficiency (57 %), and autism (75 %). TS
type 2 is characterized by the presence of extreme prolonga-
tion of the QT but absence of syndactyly. TS patients die at an
average of 2.5 years, and the leading cause of death is ven-
tricular tachycardia. Thus, as is common with syndromic
forms of autism, morbidity caused by autistic behaviors is a
relatively minor aspect within a large spectrum of severe
clinical manifestations (Splawski et al. 2006).
Dolmetsch and colleagues generated cortical-enriched neu-
ronal populations differentiated from several hiPSC lines de-
rived from two type-1 TS patients and showed that mutant
neurons exhibit action potentials wider than those of control
cells, in agreement with a loss of CaV1.2 channel inactivation
caused by the mutation (Pasca et al. 2011). Calcium imaging
in cortical progenitors and in synapsin-positive mature neu-
rons revealed an increase in the sustained intracellular calcium
rise following membrane depolarization, strongly suggesting
that TS NPCs and neurons have deficiencies in calcium sig-
naling, with concomitant changes in activity-dependent gene
expression. Remarkably, TS neuronal cultures contained more
cells expressing tyrosine hydroxylase and produced more
norepinephrine and dopamine, a phenotype also observed in
the valproic acid model of ASD (D'Souza et al. 2009). Unex-
pectedly, of those neurons in the culture that expressed lower
layer cortical markers, TS neurons also contained fewer cells
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expressing SATB2, critical for formation of corpus callosum
projection neurons. This observation was confirmed in a
transgenic mouse model expressing the mutant channel under
the forebrain-specific FOXG1 promoter (Pasca et al. 2011).
Thus, these results indicate that neuronal specification deficits
caused by TS mutations can be recapitulated in both hiPSC-
derived neurons and mouse models. The study also under-
scores the fact that differentiation of hiPSC-derived neurons of
appropriate subtypes is critical to reveal alterations in neuronal
specification, as such changes may contribute to neural cir-
cuitry dysfunction in ASD patients.
A mouse model of type 2 TS showed robust behavioral
phenotypes reflecting the three core traits of autism, including
restricted, repetitive, and perseverative behaviors, reduced
socialization with other animals, and altered ultrasonic vocal-
ization (Bader et al. 2011). Although analyses of alterations in
neuron morphology and function or brain circuitry that may
underlie these behaviors were not reported in this study, a
similar mouse model was recently constructed and character-
ized by Dolmetsch and colleagues (Krey et al. 2013). CaV1.2
couples changes in membrane potential to dendritic arboriza-
tion, possibly by recruiting small GTP-binding protein family
members, which in turn regulate signaling controlling arbor-
ization. Frontal cortex layer 2/3 pyramidal neurons from TS
mice showed a decrease in total basal dendritic length and the
number of dendritic branches by postnatal day 14, indicating a
net reduction in basal dendritic complexity in an early post-
natal phase. Importantly, these effects on activity-dependent
dendritic refinement were also observed in vitro, using both
primary rat cortical neurons and several hiPSC neuronal lines
from the two type-1 TS patients. Detailed analyses revealed
that mutant CaV1.2 channels are deficient in recruiting suffi-
cient levels of the small GTP-binding protein Gem, thus
causing excessive activation of RhoA and activity-dependent
dendritic retraction independent of calcium signaling
(Krey et al. 2013). These insights highlight that hiPSC
modeling of ASD requires assays tailored to the known
function of the affected gene to unravel pathophysiolog-
ical mechanisms. The study also illustrates the value of
a complementary approach that includes evidence from
rodent and human cellular models and in vivo rodent
data.
Fragile X syndrome
Fragile X syndrome (FXS) is an X-linked dominant
disorder and the most common form of inherited intel-
lectual disability, affecting ∼1 in 4,000 newborns
(Coffee et al. 2009). Clinically, FXS is characterized
by mild to severe cognitive deficits and behavioral
abnormalities that include hyperactivity and autism-like
behaviors (Gallagher and Hallahan 2012). The syndrome
is caused by the absence of expression of the fragile X
mental retardation 1 (FMR1 ) gene, coding for the RNA
binding protein FMRP. Typically, loss of FMRP in FXS
is caused by abnormal CGG triplet repeat expansion in
the 5′ untranslated region (5′ UTR) of the gene, leading
to developmentally controlled CpG methylation in the
promoter and 5′ UTR region and thus resulting in gene
silencing (Feng et al. 1995). Repeat numbers >200 lead
to complete silencing in neurons and cause FXS, while
repeat expansions in the premutation range (55–200
repeats) are associated with upregulation of FMR1 ex-
pression and cause the late onset neurodegenerative
disease, fragile X associated tremor ataxia syndrome,
probably via a toxic gain of function of the CGG-rich
RNA transcript (Gallagher and Hallahan 2012).
Although a mouse model carrying ∼230 repeats did not
recapitulate the abnormal methylation of the promoter and 5′
UTR methylation seen in humans (Brouwer et al. 2008),
Fmr1 knockout mice display many features of FXS, including
autistic behaviors (Consortium TD-BFX 1994). FMRP, a
suppressor of messenger RNA translation, is required for
activity-dependent regulation of synaptic protein synthesis,
which is stimulated by activation of group 1 mGluRs, includ-
ing mGluR5. Since many of the long-term consequences of
mGluR5-mediated signaling, including LTD, are dependent
on protein translation, it has been hypothesized that mGluR5
inhibition could counteract neuronal dysfunction in FXS
(Bear et al. 2004). Indeed, strong support for the “mGluR5
hypothesis for FXS” theory comes from several recent studies
in which pharmacological or genetic intervention aimed at
reducing mGluR5-dependent signaling prevented and/or
reverted FXS phenotypes (Dolen et al. 2007; Michalon et al.
2012; Silverman et al. 2012).
Human ESCs derived from FXS-affected blastocyst-stage
embryos express FMRP and gene silencing via promoter
methylation occurs only upon differentiation (Eiges et al.
2007). In contrast, hiPSCs derived from fibroblasts of affected
patients showed deoxyribonucleic acid (DNA) methylation
and transcriptional silencing even in the pluripotent stage,
indicating that somatic reprogramming did not erase these
chromatin marks (Urbach et al. 2010). Thus, although these
hiPSCs do not recapitulate developmentally regulated FMR1
silencing, they may nevertheless represent a useful model
system for screening of compounds capable of reactivating
the gene (Bar-Nur et al. 2012). Differentiation of hiPSCs
towards neurons showed reduced neurite numbers and neurite
lengths (Sheridan et al. 2011), phenotypes that resemble those
seen in the Fmr1 knockout mouse (Braun and Segal 2000;
Luo et al. 2010) and in human FXS postmortem tissue
(Castren et al. 2005). In the future, it will be important to
address whether FXS hiPSC-derived neurons display exag-
gerated mGluR5 signaling and defects in LTD and, if so,
whether these phenotypes can be reverted with mGluR5
inhibitors.
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ASD modeling in a dish: towards neuronal circuits
An outstanding question is whether hPSC-derived neurons
will be useful for identifying new therapeutic targets and for
developing disease-relevant phenotypes for high throughput
screens. The ability to study diseases of the cerebral cortex
in vitro and to observe disease-relevant phenotypes will de-
pend on the ability to produce neuronal cultures of defined
cellular composition.
Efficient neural specification using defined morphogens
Major advances in the establishment of human neuronal dif-
ferentiation protocols now nurture the hope that we may be
able to build specific cellular networks from hPSCs in the near
future. A number of groups have established robust
morphogen-based protocols to drive mouse embryonic stem
cells into neurons of specific regional and functional identity,
including dopaminergic, striatal, motor, and cortical neurons
(Hansen et al. 2011). These morphogens, together with sig-
naling through specific cell-to-cell contacts, dictate neuronal
specification by inducing signal transduction cascades
(Hansen et al. 2011). In contrast, early procedures to produce
human neural cells from hPSCs either relied on coculture with
stromal feeder cells, which induce neural conversion through
the action of undefined factors, or depended on the generation
of three-dimensional heterogeneous cellular aggregates (so-
called embryoid bodies) from which neural precursor cells
were subsequently isolated. Both approaches yielded neuronal
cultures of variable cellular composition and quality. More
recently, however, chemically defined protocols that induce
rapid and virtually complete neural conversion have been
developed; these should ultimately lead to standardized strat-
egies for driving differentiation of hPSCs to relevant neuronal
cell types.
A major breakthrough was the development of protocols
that robustly, reproducibly, and efficiently convert hPSCs into
neural ectoderm tissue. Noggin, a bonemorphogenetic protein
inhibitor, had previously been demonstrated to have robust
neural-inducing properties (Pera et al. 2004). Similarly, the
small molecule SB431542, which inhibits the Lefty/activin/
transforming growth factor beta pathways by blocking phos-
phorylation of the ALK4, ALK5, and ALK7 receptors, en-
hances neural induction in hPSCs (Patani et al. 2009). The
combination of noggin and SB431542 (dual SMAD inhibi-
tion), then enabled rapid and uniform neural induction of
hPSCs under adherent culture conditions, and allowed the
derivation of relevant neuron subtypes in a shorter time
(∼19 days) (Chambers et al. 2009). Others have reported
similarly efficient neural induction in both hESCs and hiPSCs
with the small molecule dorsomorphin in place of noggin
(Kim et al. 2010). Although the dual SMAD inhibition pro-
tocol in its original form gives rise to a heterogeneous
population of neuronal cell types (both telencephalic and
diencephalic), recent modifications have enabled the deriva-
tion of more specialized neuronal precursor and mature neu-
ron populations, including floor plate precursors, midbrain
dopaminergic neurons, and cortical neurons (Fasano et al.
2010; Kriks et al. 2011; Shi et al. 2012c).
Accelerating differentiation towards homogeneous neuronal
populations
HPSC-derived neurons presently require long maturation
times to reach a level of neuronal connectivity that allows
the study of synaptic physiology (60–120 days). In order to
facilitate adaptation of these cultures for drug screening, future
improvements will therefore have to focus on assessing syn-
aptic physiology and accelerating neuronal maturation. For
example, in several studies, electrophysiologically active hu-
man neurons initially exhibit immature properties, including
smaller, slower action potentials and the inability to fire repet-
itively, in contrast to more mature neurons (Shi et al. 2012c).
Thus, baseline intrinsic membrane properties (e.g., resting
membrane potential, input resistance) and action potential
firing properties (e.g., threshold, amplitude, rise time), as well
as percentages of neurons with differing firing rates, define the
degree of differentiation, and should be systematically moni-
tored while optimizing neuronal protocols to model synaptic
dysfunction.
Modeling neuronal circuitry deficits and properties of spe-
cific synapses, such as cortico-striatal and excitatory/
inhibitory connections, requires cultures that are highly
enriched for specific neuronal subpopulations. Fluorescence-
activated cell sorting (FACS) has been used to isolate hiPSC-
derived neural crest cells (Lee et al. 2009), NPCs, and even
mature neurons (Israel et al. 2012; Yuan et al. 2011). The use
of specific combinations of neuronal cell surface markers may
thus allow the prospective isolation of additional neuronal
lineages. Significantly, in their study of hiPSC-derived neu-
rons from patients with Alzheimer's disease, Goldstein and
colleagues used FACS-based purification to reduce the vari-
ability in the efficiency of neuronal differentiation between
hiPSC lines, providing increased power to identify disease-
related changes (Israel et al. 2012). The identification of
additional cell surface neuronal markers of specific subtypes,
particularly middle and upper layer cortical neurons and in-
hibitory neurons, will facilitate progress towards pure popu-
lations of specific cortical subpopulations. Although not ex-
plored in hPSCs to date, reporter constructs expressing green
fluorescent protein, under the control of a lineage-specific
promoter, may be generated by genome editing, allowing the
enrichment of additional neuronal lineages, including those
for which cell surface markers are not known.
Figure 2 shows that using proliferating hPSC-derived
NPCs as a starting point for differentiation dramatically
Psychopharmacology (2014) 231:1089–1104 1097
shortens the time required to obtain mature neurons with gene
expression profiles approximating that of human brain. Addi-
tional modulation of the composition of the differentiation
factor cocktail can modestly accelerate maturation (Fig. 2).
One exciting recent approach towards further speeding up
differentiation and generating homogenous cell populations
is direct lineage conversion from non-neuronal cells by the
forced expression of neuronal transcription regulators (Pang
et al. 2011; Vierbuchen et al. 2010). Overexpression of the
forebrain transcription regulators ASCL1, BRN2, ZIC1,
MYT1L, and OLIG2 directly converts human fibroblasts into
neuronswith forebrain glutamatergic propertieswithin 21 days
(Qiang et al. 2011). However, fibroblasts have limited prolif-
erative capacity in vitro, thus limiting the number of cells
available from a patient biopsy. Dopaminergic neurons
(Sanchez-Danes et al. 2012a) and motor neurons (Hester
et al. 2011) have been generated from hPSCs and NPCs by
combining different sets of transcription factors, indicating
that subtype-specific neuronal differentiation can be
achieved. Such “induced neurons” from Alzheimer's and
Parkinson's patients have shown disease-relevant cellular
phenotypes (Qiang et al. 2011; Sanchez-Danes et al.
2012a,b). Although this approach may help reduce some
of the variability in cellular homogeneity associated with
current morphogen-based procedures, it is clear that dif-
ferentiation by forced transgene expression may not allow
the observation of subtle defects in neuronal specification
and maturation, such as those observed in TS neurons
(Pasca et al. 2011). Thus, although the usefulness of
induced neurons in modeling the molecular and cellular
defects of neurodegenerative diseases has been demon-
strated, it remains to be seen whether they can also gen-
erate neurons capable of supporting a neuronal network
relevant to neurodevelopmental disorders.
Cortical specification
Relatively simple differentiation protocols, such as the one
used to generate the neurons analyzed in Fig. 2, can generate
neurons that approximate the gene expression pattern of hu-
man cortex. However, these neurons do not recapitulate the
elaborate cortical layer-specific specification seen in vivo.
Particularly relevant to ASD disease modeling, inclusion of
retinoic acid in the dual SMAD inhibition procedure leads to
cortical neuron identity, based on the appearance of cortical
projectionmarkers in precursors, which subsequently give rise
to upper and lower layer cortical projection neurons (Shi et al.
2012c). Remarkably, all classes of cortical projection neurons
found in vivo are generated and the temporal order of their
emergence recapitulates in vivo cortex development. Impor-
tantly, between 60 and 120 days after the onset of neuronal
derivation, the retinoic acid/dual SMAD inhibition protocol
yields mature cortical neurons with appropriate electrophysi-
ological properties and functional synapses (Michaelson et al.
2012; Shi et al. 2012a,b). Prolonged exposure to noggin
resulted in robust induction of telencephalic/cortical genes,
while shorter treatments yield a mixture of diencephalon and
telencephalon induction, but the in vitro temporal sequence of
generation of cortical neuron types again followed in vivo
development. When cortical pyramidal neurons generated in
vitro were transplanted into mouse neonatal brain, they devel-
oped axonal projections and dendritic morphology which
corresponded to endogenous cortical neurons. Thus, the fact
that neurons generated in vitro develop properties of human
cortical neurons in vivo offers an unprecedented opportunity
to study ASD both in vitro and in animal xenograft models.
These recent studies bring hope that specific cortical
neuronal circuitry can be modeled using hPSCs relevant
to ASD. Given that the expanded upper layers of the
cortex are a cardinal feature of the human cortex, the
specific generation of these neurons from hPSCs has
potential for revealing specific aspects of cortical cir-
cuitry dysfunction in ASD.
Fig. 2 Transcriptome analyses validate the relevance of hPSC-based
models of neuronal differentiation. Principal component analysis (PCA)
of the expression profiles of 4,818 genes of postmortem tissue samples
from human cerebellum and frontal and temporal cortex (Voineagu et al.
2011) are compared to the expression profiles of hESC-derived neural
progenitor cells (NPCs) and their differentiated progeny (our unpublished
work). NPCs were generated from hPSCs by dual SMAD inhibition and
differentiated for 7–35 days (D) in medium containing BDNF, glial-
derived neurotrophic factor, ascorbic acid and dibutyryl-cyclic adenosine
monophosphate (+BGAA), or in basal medium (−BGAA). The analysis
shows that transcriptomic profiles of neuronal cultures differentiated for
35 days more closely approximate that of human cortex than of cerebel-
lum, suggesting cortical-like properties. Inclusion of BGAA increases the
kinetics and/or extent of neuronal maturation
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Neuronal circuits
MRI studies and postmortem analyses of autistic individuals
have consistently demonstrated anatomical abnormalities in
several brain regions (including cortical frontal lobe, striatum,
amygdala, and cerebellum), while functional MRI studies
found differences in the activity of specific brain areas during
cognitive tasks when compared to neurotypical controls
(Amaral et al. 2008; Schumann and Nordahl 2011). Thus,
meaningful relationships will need to be established between
the cellular, molecular, and network-based properties of
hPSC-based models of ASD, on the one hand, and the ana-
tomical and functional endophenotypes of ASD patients'
brains, on the other. In cellular models of ASD, disease-
relevant dysfunction may reveal itself at distinct levels of
functional complexity within the cell population (Fig. 3).
The different phenotypic trajectories of different hPSC-based
ASD models likely converge at several levels of functional
complexity as well, illustrating the requirement for mature,
synaptically connected neurons capable of sustaining a neu-
ronal network (Fig. 3).
Aberrant neuronal network activity is strongly implicated
as directly underlying many forms of brain dysfunction, in-
cluding ASD. In particular, disruptions in the balance between
excitatory/inhibitory (E/I) inputs have been observed in both
ASD patients and mouse models of the disorder, pointing
towards neural circuit dysfunction as the convergence point
of pathophysiological trajectories that originate from diverse
etiologies (Penzes et al. 2013). For example, Cntnap2 knock-
out mice, lacking a gene associated with ASD, show reduced
numbers of GABAergic interneurons and decreased neuronal
synchrony in the cortex (Penagarikano et al. 2011). Moreover,
ASD mouse models engineered to display disinhibition of
eIF4E-dependent control of protein synthesis have a de-
creased ratio between inhibitory and excitatory synaptic inputs
(Gkogkas et al. 2013; Santini et al. 2013). Thus, the relevance
of hPSC-based cellular models for ASD ultimately hinges on
the successful in vitro generation of functional neuronal net-
works, characterized by synaptically connected excitatory and
inhibitory neurons at physiologically relevant proportions.
Given the different developmental origins and lineages of
excitatory cortical pyramidal neurons and inhibitory
Fig. 3 Towards cellular models of neuronal network dysfunction. Shown
here are the principal stages of differentiation of hPSCs towards synap-
tically competent mature neurons. a First, neural ectoderm induction
generates characteristic three-dimensional rosette-like structures express-
ing the transcription factor PLZF and the tight-junction protein ZO1
(upper). From these, neuroepithelial precursors expressing NPC markers
Sox2 and nestin can be isolated and expanded (lower). b Further differ-
entiation yields neurons extending MAP2a/b-positive dendrites. c Ma-
turing neurons show colocalized synaptic markers, such as the presynap-
tic marker synapsin and the postsynaptic density protein SHANK3. d
Mature neuronal cultures form functionally connected neuronal networks,
characterized by synchronized spontaneous network activity seen in
recordings from multi electrode arrays. Pathways dysregulated in differ-
ent forms of ASD may converge on the cellular and molecular levels,
allowing identification of early phenotypes in neuronal cultures from
patient-derived hiPSCs. Such phenotypes include the identification of
translational and transcriptional dysfunction which at the cellular level
may be associated with abnormal proliferation and differences in extent
and kinetics of early neuronal differentiation. Other pathways may con-
verge at the synapse level, requiring mature neurons with synaptic con-
nections. Dysregulation at the neuronal connectivity level due to synaptic
dysfunction may only be identified in human neuronal cultures forming
relevant neuronal circuits that resemble those of the human cortex
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interneurons, it remains a challenge to simultaneously produce
both cell types in appropriate ratios from the same culture.
Their separate generation by different protocols and subse-
quent coculture may provide a way forward. Indeed, protocols
have recently been devised to direct the differentiation of
hPSCs towards progenitors resembling those of the medial
ganglionic eminence and further into forebrain interneurons
(Nicholas et al. 2013) .
In the brain, inhibitory interneurons play a critical role in
maintaining neural synchrony of oscillatory activity in local
circuits (Huang et al. 2007). Since defects in synchrony are
associated with neuropsychiatric disorders including ASD and
schizophrenia (Penzes et al. 2013), there has been much
interest in establishing neuronal in vitro cultures capable of
supporting such synchronous activity. In their study of hiPSC-
derived neurons from patients with schizophrenia, Brennand
et al. (2011) observed reduced neuronal connectivity and
glutamate receptor expression but, surprisingly, no abnormal
synapse-dependent synchronous activity. Thus, it may be
ambitious to expect that we can replicate complex brain
network oscillations in an in vitro system. Nevertheless, syn-
chronization is a sensitive measure of the maturity and con-
nectivity of such in vitro neuronal networks, and so this
functional readout may help reveal defects in network prop-
erties that are too subtle to be detected by cellular assays.
Synchronous network activity can be monitored by culturing
neurons on MEAs (Fig. 3) or by measuring intracellular
calcium transients using Ca2+-sensitive dyes applied to neu-
ronal cultures. MEAs allow repeated measurements of differ-
entiation cultures over time, allowing investigation of matu-
ration kinetics. In contrast to electrophysiological approaches,
calcium imaging is amenable to higher-throughput assay for-
mats, allowing the development of drug screens using hPSC-
based cellular models of ASD. When combined with subse-
quent immunocytochemistry, specific neuronal subtypes
(such as excitatory vs. inhibitory neurons) or subnetworks of
cells that show aberrations in their network behavior can be
identified. Owing to these advantages, it is therefore likely that
measurement of network properties by calcium imaging will
be one of the key technologies in translational ASD research.
Outlook
The key to understanding the pathophysiology of ASD and
the development of therapeutics is the development of robust
disease-relevant cellular models. These efforts comprise (1)
establishing hiPSCs from biopsy material of ASD patients
with diverse genetic etiologies and from neurotypical control
individuals, (2) genetic engineering of normal hPSCs to gen-
erate matched isogenic sets of lines with targeted ASD-
relevant genetic defects, (3) the development of robust, effi-
cient and relevant neuronal differentiation protocols, and (4)
the definition of ASD-related cellular phenotypes upon which
corresponding cellular assays can be built. The design of these
models and assays will need to be continuously informed and
guided by insights from mouse models and from genetic,
molecular, and functional studies in the ASD population.
Given the diverse genetic and clinical landscape of ASD
patients, it is evident that a single cellular model will not
recapitulate all aspects of ASD pathology from all ASD
patients. Nevertheless, our increased appreciation that differ-
ent pathophysiological trajectories may converge on a limited
set of molecular pathways fuels the hope that a limited number
of cellular models may address a majority of relevant pheno-
types. Major inroads into all these areas have been built in the
recent past: the time is now ripe for hPSCs models to be
implemented in ASD discovery research.
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